



Tolebrutinib for Secondary Progressive Multiple Sclerosis: Effectiveness and Value

Friday • June 13, 2025 • 9:00 AM – 3:00 PM PT

| Time (PT) | Activity |
|-------------------|---|
| 9:00 AM—9:20 AM | Meeting Convened and Opening Remarks Sarah K. Emond, MPP, President and CEO, ICER |
| 9:20 AM—10:00 AM | Presentation of the Clinical Evidence Grace Lin, MD, MAS, Medical Director for Health Technology Assessment, ICER Associate Professor of Medicine and Health Policy, UCSF |
| 10:00 AM—10:40 AM | Presentation of the Economic Model Brett McQueen, PhD, Associate Professor, University of Colorado Anschutz Medical Campus |
| 10:40 AM—11:00 AM | Public Comments and Discussion |
| 11:00 AM—11:50 PM | Lunch Break |
| 11:50 AM—12:50 PM | CTAF Vote on Clinical Effectiveness and Value Moderator: Ralph G. Brindis, MD, MPH, MACC, FSCAI, FAHA, Clinical Professor of Medicine at the University of California, San Francisco (UCSF) |
| 12:50 PM—1:00 PM | Break |
| 1:00 PM—2:30 PM | Policy Roundtable Moderator: Sarah K. Emond, MPP, President and CEO, ICER |
| 2:30 PM—3:00 PM | Reflections from CTAF |
| 3:00 PM | Meeting Adjourned |

Connect with ICER on our social media channels



ICER's value assessments are free from financial conflicts of interest from health care companies. As an organization, we value transparency and hold ourselves, and our collaborators, to high standards for conducting our work. Our full policy to manage potential conflicts of interest can be found [here](#). You can find ICER's Code of Ethics [here](#). Any disclosures by participants of the public meeting can be found [here](#).

| ICER Staff and Consultants | Conflict of Interest Disclosure |
|---|---|
| Foluso Agboola, MBBS, MPH , Vice President of Research, ICER | No conflicts to disclose. |
| Sarah Emond, MPP , President and Chief Executive Officer, ICER | No conflicts to disclose. |
| Grace Ham, MSc , Senior Program and Events Coordinator, ICER | No conflicts to disclose. |
| Grace Lin, MD , Medical Director for Health Technology Assessment, ICER | Financial support is provided to UCSF and Dr. Lin from the Institute for Clinical and Economic Review (ICER). |
| Brett McQueen, PhD , Associate Professor, University of Colorado Anschutz Medical Campus | Dr. McQueen has received compensation from Sanofi for a special speaker series in April 2024 related to type 1 diabetes and fees for reviewing a project attempting to improve early diagnosis of type 1 diabetes. He has not received any funding directly related to a product or directly related to multiple sclerosis. |
| Shahariar Mohammed Fahim, PhD , Research Lead, ICER | No conflicts to disclose. |
| Marie Phillips, BA , Research Assistant, ICER | No conflicts to disclose. |
| Becca Piltch, MPP , Program Manager, ICER | No conflicts to disclose. |
| Finn Raymond, BS , Research Assistant, ICER | No conflicts to disclose. |
| Marina Richardson, PhD, MSc , Associate Director, HTA Methods and Health Economics, ICER | No conflicts to disclose. |
| Antal Zemlenyi, PhD, MSc , Visiting Research Associate, University of Colorado Anschutz Medical Campus | Financial support provided to the University of Colorado from the Institute for Clinical and Economic Review (ICER). |

| Participating Members of CTAF | Conflict of Interest Disclosure |
|---|--|
| Ralph Brindis, MD, MPH Professor of Medicine, UCSF | Dr. Ralph Brindis holds stock options in GENinCode issued to him for consulting performed for the company. These options are not currently vested and have no value. Dr. Brindis will provide ICER with an update to the value of these stock options if they are converted to stock to ensure that the value does not exceed ICER's Policies to Manage Conflicts of Interest. |
| Robert Collyar Patient Advocate, Patient Advocates in Research | No conflicts to disclose. |
| Paul Heidenreich, MD, MS Professor of Medicine, Stanford University | No conflicts to disclose. |
| Jeffrey Hoch, MA, PhD Professor, University of California, Davis | No conflicts to disclose. |
| Jeff Klingman, MD Emeritus Chair of Neurology, The Permanente Medical Group | No conflicts to disclose. |
| Annette Langer-Gould, MD, PhD | Kaiser Permanente plans to enroll patients in a multi-center RCT for non-relapsing secondary progressive |

| | |
|--|---|
| Regional Lead for Clinical and Translational Neuroscience, Kaiser Permanente Southern California | multiple sclerosis. While Kaiser Permanente will receive funding from Sanofi to support study personnel, Dr. Langer-Gould does not receive any salary support or other type of compensation. |
| Sei Lee, MD, MAS Professor of Medicine, UCSF | No conflicts to disclose. |
| Joy Melnikow, MD, MPH Professor emeritus, University of California Davis | Dr. Melnikow received \$8750 from ADVI for consulting on the USPSTF process in 2024. |
| Lisa Murphy, MD, DPhil Professor of Medicine, UCSF | Dr. Murphy royalties via UCSF \$1166.66 from a company that licensed the technology. Dr. Murphy gives CME talks to "Big Island Docs" in Hawaii. She receives travel reimbursement from the organization. |
| Kathryn Phillips, PhD Professor, Health Economics, UCSF | Dr. Phillips received \$20K in consulting income from Illumina to Chair a Global Economics working group. She finished her service as Chair as of Dec 2024. She expects to later receive \$2500 for a presentation to Danaher May 29th on biomarker testing for Alzheimer's disease. |
| Rita Redberg, MD, MSc Professor of Medicine, UCSF | No conflicts to disclose. |
| Joanna Smith, MSW, MPH Healthcare Advocate, Joanna Smith, LCSW | No conflicts to disclose. |
| Tony Sowry, MA National Patient Advocate Foundation | No conflicts to disclose. |

| Policy Roundtable Participant | Conflict of Interest Disclosure |
|--|--|
| Robert Bermel, MD, MBA, FAAN , Director, Mellen Center for Multiple Sclerosis, Cleveland Clinic | Dr. Bermel has served as a consultant for Genzyme/Sanofi, Genentech/Roche, Novartis, and TG Therapeutics and received consulting fees in excess of \$5,000. He also serves as a volunteer member of the Medical Advisory Board, which has received >25% of its funding from healthcare companies. |
| Kathleen Costello, CRNP, MSCN , Interim CEO, Consortium of MS Centers; President, Multiple Sclerosis Foundation | The Consortium of MS Centers and Can Do MS receive sponsorships and educational grants from the following Pharmaceutical Companies: Amgen, Biogen, EMD Serono, Bristol Myers Squibb, Genentech, Kyverna, Novartis, Sandoz, Sanofi, Octave Bioscience, TG Therapeutics, Vanda and Viartis. Kathleen Costello has no personal disclosures. |
| Aaron Dush, PharmD , Senior Clinical Pharmacist, UnitedHealthcare | Dr. Dush is a full-time employee of UnitedHealthcare. |
| Lisa Farnett, PharmD , Global Medical Director, Sanofi | Dr. Farnett is a full-time employee of Sanofi. |
| Nancy Garcia, MTS, BCC , Retired Chaplain | No conflicts to disclose. |
| Ellen Mowry, MD, MCR , Professor of Neurology & Epidemiology, Johns Hopkins University | Johns Hopkins University has received funding from Roche/Genentech and Biogen. |
| Jeff White, PharmD, MS , Staff Vice President, Clinical Pharmacy Services, Elevance Health | Dr. White is a full-time employee of Elevance Health. |